PDA

View Full Version : ALRT ALR Technologies Inc. OTC



Adjistyync
08-10-2015,
ALRT has a channel pattern which is also a flag pattern. The flag pattern is bullish and the break of the channel pattern is bullish. ALRT has a very good chance of breaking this pattern and making a move up. I will be watching closely for an entry.....

Shares Outstanding5: 213.53M
Float: 86.03M
% Held by Insiders6: 58.74%
Revenue (ttm): 5.00K
Total Debt (mrq): 6.03M

ALRT Chart

ADreattylilt
08-13-2015,
ALR Technologies Inc.
3350 Riverwood Parkway
Suite 1900
Atlanta, GA 30339
United States - Map
Phone: 678-881-0002
Website: Alrt Technology Solutions

Details
Index Membership: N/A
Sector: Services
Industry: Medical Equipment Wholesale
Full Time Employees: N/A


Business Summary

ALR Technologies Inc. designs, markets, and develops medication compliance reminder devices and compliance monitoring systems primarily in the United States. Its products include ALRT Health-e-Connect System, a health management compliance monitoring system, which allows health care professionals to program compliance reminders for patients with chronic conditions, such as diabetes, chronic obstructive pulmonary disease, and other disease states; and Constant Health Companion, a product that reminds with audio beeping sound and displays actions to take on LCD screen. The company’s products also comprise Home Monitoring System that allows a treatment center and other health care professionals to remotely change patient's reminder timing and/or the actions/doses/medications to take at the time of each reminder serving heart disease patients, organ transplant recipients, cancer patients, severe diabetics, HIV patients, and patients with other chronic diseases. In addition, it offers ALALRT Health-e-Connect System for diabetes monitoring, a communications software platform that enables health professionals to remotely monitor the health progress of diabetic patients; and ALRT Health-e-Connect System for respiratory health management, which enables physicians and caregivers to monitor the use of the nebulizer, the time of day used, and the duration of time used. Further, the company provides vision care and contact lens replacement reminders; reminders for vitamins; nutrition and weight management programs; and reminders for medications for companion animals. Its target market consists of patients with diabetes and chronic obstructive pulmonary disease, as well as with cystic fibrosis, transplant patients, congestive heart failure, coronary artery disease, and cancer. The company was formerly known as Mo Betta Corp. and changed its name to ALR Technologies Inc. in December 1998. ALR Technologies Inc. was founded in 1987 and is based in Atlanta, Georgia.

ALRT.OB Profile | ALR TECHNOLOGIES INC Stock - Yahoo! Finance
__________________
"People are not remembered by how few times they fail, but how often they succeed."
- Thomas Edison


Articles by Gwitt
http://www.triond.com/users/GWitt

adufutuvorug
08-13-2015,
New Technologies to Contain Waste in Diabetes Test Supplies

Opportunity for Medicare to Reduce Millions in Costs

At the same time that the federal government seeks to cut Medicare spending, awareness is growing about a fraudulent practice around diabetes test strips that is running up program costs and putting the health of patients at risk.

At the heart of the issue is the need for patients with diabetes to test their blood glucose levels regularly. Knowing blood glucose levels allow patients to alter their diabetes management strategy if the levels are not near the target.1 Doctors prescribe test strips to patients with diabetes to be used as part of their care plans. It is possible that a portion of test strips paid for by Medicare and other insurers are not used by many patients. Nevertheless, patients covered by health insurance are often resupplied with blood glucose test strips whether or not they have used up their prescription. As stated by Doug Hoey, CEO of the National Community Pharmacists Association in an article by HME News2, "We have heard stories of boxes and boxes of strips being sent to patients, charged to Medicare and the patient can't use them fast enough," he said. "Or the patient is deceased and the supplies continue to mount up at the home.”

Some of the unused test supplies are sold in the black market. While test strips can be legitimately purchased over-the-counter for cash price by anyone, the second-hand sale of these test strips is fraudulent if the strips were obtained through a prescription and reimbursed by Medicare/Medicaid. As such, the term “black market” is often replaced by “gray market” given the fact that selling test strips is not illegal in and amongst itself.

Awareness, outrage, and a call for action are beginning to build around the issue of the black market sale of test strips. Several local television stations have exposed the practice this year. CBS Denver was one of the first to break the story back in February 2011 with their broadcast of “CBS4 Investigates Black Market Diabetes Test Strips”3 exposing “an alarming practice that has the director of one of the nation’s leading diabetes centers and journals issuing a warning to patients.” The alarming practice at the center of the report: the buying and selling of diabetic test strips on the Black Market. A practice that could ultimately cost a person with diabetes their life as recalled, expired and counterfeit strips are bought and sold daily. Only a few weeks later, KENS in San Antonio, Texas followed with a report of its own4.

According to the 2011 National Diabetes Fact Sheet5, 25.8 million people in the United States are affected by diabetes with associated healthcare costs of approximately $175 billion per year (for the year 2007). Many diabetes patients do not have adequate insurance to cover the cost of test strips. Monthly supplies for can run into hundreds of dollars. As the person with diabetes in a Fox Baltimore report6 explained, “Not everybody has the kind of good insurance that I have, and this is really expensive stuff.”

Research7 has shown that through proper monitoring of blood sugar levels and adherence to care plans, diabetes patients are healthier and require fewer visits to the doctor than those who are non-compliant. The importance of following strict procedures in proper diabetes care is best summarized by William Herman, M.D., M.P.H.8, one of the world’s foremost experts on diabetes, in stating, “It’s now well-proven from scientific studies that diabetes control matters, and that better sugar control over years and decades is associated with a reduced risk of complications affecting the eyes, the kidneys, the nerves, heart and blood vessels.” Using test strips that do not meet FDA standards such as many of those sold on the Black Market can result in inaccurate data from faulty strips leading to dire consequences.

One possible solution: to account for the usage of prescribed test strips before more can be provided to the patients. This is possible, as every major provider of blood glucose meters – Abbott, Bayer, LifeScan (a Johnson & Johnson company), Nipro and Roche - has the technology to handle verification of test strip usage. However, because meters from each of these manufacturers are designed slightly differently and vendors of these supplies are faced with the onerous task of pulling the data separately for each system, a clear need exists for a cross-platform technology to bridge the gaps between manufacturers. A few companies have addressed this challenge already.

HealthVault by Microsoft? (NASDAQ: MSFT), WellDoc, and the Health-e-Connect (HeC) System by ALR Technologies (OTCBB: ALRT) all are in the mobile health space and offer potential solutions to the cross-platform dilemma. Juxtaposing the technologies, however, reveals some stark differences.

HealthVault, which does not have Food and Drug Administration 510(k) clearance, is a personal health record storage solution similar to what many companies are doing in the burgeoning electronic medical records arena.
WellDoc has conducted clinical trials comparing their system to traditional practices of diabetes care by measuring A1c (the standard measure for diabetes control) with positive results. The importance of patient compliance to prescribed blood sugar testing was confirmed in WellDoc’s research to reduce A1c levels. The caveat to WellDoc’s system is that it relies on patients to manually entering data into a cell phone several times a day. Manual (user) data entry has been shown through other studies to be time consuming, inconsistent, and an inaccurate representation of actual use.

ALR Technologies’ HeC System, a chronic disease management technology, covers the complete range of compliance and documentation. The HeC System has also been successfully used in clinical trials9 as part of intensive blood glucose monitoring programs. Cleared by the FDA in October for remote monitoring of patients in support of effective diabetes management programs, HeC is a cross-platform system compatible with all the major manufacturers’ blood glucose meters which allows test results stored in a meter to be uploaded. The data is organized for the respective needs of patients, clinicians, test supply vendors and insurers, whether it be encouraging patient compliance or documenting strip count for reimbursement and refill requirements. ALR’s platform also allows for mobile alerts reminding diabetes patients that it is time to test their blood glucose levels.

The Black Market offerings and the subsequent risks involved are not going to disappear on their own, nor will the exorbitant waste of funds relating to non-documented strip reimbursement. Fortunately, steps have been taken in the past to combat similar problems; such as when Medicare and many private insurers began mandating the verification of use for CPAP machines to allow reimbursement for sleep apnea. Given this precedent and the mounting awareness of strip count fraud, it is easy to envision the government taking similar actions to deal with the issues surrounding diabetes test strips. Such action would exponentially grow the usage of technologies such as the HeC System. Medicare provides coverage to 10.9 million diabetes patients and pays over $1 billion* a year for test strips alone.5 10 11 12 13 With the financial pressures in the healthcare industry to regulate costs and provide better disease management, it would seem likely that further actions are imminent.

aexeniciey
08-13-2015,
The New York Times published an article this past weekend titled, “Health Official Takes Parting Shot at Waste.” Written by Robert Pear, the article focuses on commentary from Dr. Donald M. Berwick, the newly departed former administrator of the Centers for Medicare and Medicaid Services (CMS).

Of particular interest is Dr. Berwick’s opinion that, “Twenty percent to thirty percent of health spending is “waste” that yields no benefit to patients, and that some of the needless spending is a result of onerous, archaic regulations enforced by his agency.” The doctor’s estimates of this “waste” amounts to between $150 billion and $250 billion per year -- monies that are desperately needed in reducing our country’s enormous debt problem and that could also go toward providing better health care service.

Where does this waste come from? Examples of excessive waste abound in the Medicare and Medicaid system. Just one example: the multitude of unused diabetes test strips prescribed for patients to self-monitor their blood glucose levels. Even though they are paid for by CMS, many of these strips are never used. More outrageously, some of the unused test strips are even “resold” on the gray market. This waste and even outright abuse of the system are enabled because CMS does not require adequate accountability of if these test strips are used before paying for refills.

We as a nation simply can’t afford to continue spending like this without better accountability and reform. Given the state of the healthcare system and the well-publicized needs for reform, change will inevitably happen; it’s just a matter of when. Investors will be glad to know that there are countless junior companies well-positioned to capitalize on fundamental shifts in healthcare. ALR Technologies Inc. (OTCBB: ALRT) provides a chronic disease management technology, the Health-e-Connect System, which could provide measurable benefits to CMS and those it covers in the near term. ALR received FDA 510(k) clearance for its Health-e-Connect System for remote monitoring of patients in support of effective diabetes management programs in October 2011.

Specifically, ALR Technologies manufactures a chronic disease management system – Health-e-Connect – that allows sharing of blood glucose data between patients and their providers. The platform is intended to improve patient outcomes, when used as part of an effective diabetes management program, by enabling providers to make immediate medication and lifestyle adjustments and to address patient barriers to diabetes care plan adherence. Improved patient outcomes equate to less health care spending. Health-e-Connect also tracks diabetes test strip utilization – information that could be used by dispensers to curb rampant test strip waste currently contributing to the squandering of millions of CMS dollars annually.

Possessing a similar technology, but possibly carrying upfront costs with it, PositiveID Corporation (OTCBB: PSID) received FDA clearance for its iglucose™ mobile health system for diabetes management in mid-November 2011.

The electronic medical record arena has many firms vying for space. According to Millennium Research Group, the electronic medical record market is projected to grow from less than $1 million in 2009 to more than $8.3 billion by 2016. Software and office equipment maker Xerox Corp. (NYSE: XRX) reported last week that its ACS subsidiary bought cloud-computing company The Breakaway Group to grow its electronic medical records capacities. At the ground-level price point, MMRGlobal Inc. (OTCBB: MMRF) is a leading junior in the electronic medical records space. The company is conducting business with several household names to expand their products including Eastman Kodak (NYSE: EK), Alcatel-Lucent (NYSE: ALU) and privately-held Chartis, Inc.

The original NY Times article can be viewed at: http://www.nytimes.com/2011/12/04/he...cial.html?_r=2

--------------------------

Disclaimer: Neither OTC Stocks, OTC News, OTC stock news, Small Cap Stock, Micro Cap Stocks, Stock Market Blog, OTC Stock Quotes, OTCBB News, Penny Stock News nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has been compensated twenty thousand dollars per month for three months of consultation, social media and journalism services and to manage a comprehensive investor relations/awareness program by ALR Technologies. Please read and fully understand our entire disclaimer at Disclaimer/Disclosure | OTC Showcase.
__________________
"Always bear in mind that your own resolution to success is more important than any other one thing." - Abraham Lincoln

"The heights by great men reached and kept, were not obtained by sudden flight. But they, while their companions slept, were toiling upward in the night." - Longfellow

"If the life you have created
Is founded on jealousy and hatred...
It's too late to ask questions
For you're much too old to take any suggestions"

Full Disclosure

afojagipugja
08-14-2015,
500 Million or 1 in 10 Adults Will Have Diabetes by 2030

The International Diabetes Federation (IDF) is the umbrella organization of over 200 national diabetes associations in over 160 countries. It represents the interests of the growing number of people with diabetes and those at risk. The Federation has been leading the global diabetes community since 1950, and IDF’s mission is to promote diabetes care, prevention, and a cure worldwide.

New figures from the 5th edition Diabetes Atlas (see International Diabetes Federation) indicate that the number of people living with diabetes is expected to rise from 366 million in 2011 to 552 million by 2030. IDF also estimates that as many as 183 million people are unaware that they have diabetes.

The release of these figures follows the September meeting of 193 Heads of State and government officials at the UN High Level Meeting in New York to agree on a Political Declaration on Non-Communicable Diseases (NCDs) including diabetes. This marks a major milestone for diabetes and other NCDs. Ann Keeling, CEO, International Diabetes Federation (IDF) and Chair of the NCD Alliance stated:

“World leaders have recognised the magnitude and impact of these diseases and the urgent need for action … The Declaration will accelerate international progress on diabetes and NCDs, saving millions of people from preventable death and disability."

The growth in the diabetic market should be beneficial for the Health-e-Connect (HeC) System, which is the principal product of ALR Technologies (OTCBB: ALRT). HeC is a web-based platform designed to assist healthcare providers caring for diabetes patients improve the compliance to and management of patient care plans through remote monitoring. Moreover, the system offers a solution to potentially reduce waste and cut costs to the healthcare system by electronically documenting or counting actual blood glucose test strip usage. Blood glucose test strips are a key element of self-monitoring of blood glucose (SMBG) and billions of dollars are spent each year on test strips for patients with diabetes. Through a unique communications channel, the ALRT HeC System’s platform also enables test strip suppliers to offer extra support to patients by encouraging them to be more compliant with their diabetes treatment plans. Adherence to prescribed treatment plans should improve health outcomes and reduce long-term healthcare costs by helping to prevent diabetes complications. The ALRT HeC System was successfully used in a clinical trial by type 2 diabetes patients on insulin as part of an intensive glucose monitoring program.

The HeC System supports data uploads from blood glucose meters manufactured by Abbott Diabetes Care, Bayer Diabetes Care, LifeScan Inc. (a Johnson & Johnson Company) and Roche Diabetes Care.

Down the road, ALRT plans to expand this platform to serve cover with other chronic diseases.